Rigel Pharmaceuticals (FRA:RI2) Beta: 3.4260 (As of Jun. 24, 2026)


FRA:RI2 Rigel Pharmaceuticals Inc FRA:RI2
78 GF Score
Price €29.47
GF Value €23.45
! 8 Warning Signs
View Full Analysis

What is Rigel Pharmaceuticals Beta?

Rigel Pharmaceuticals FRA:RI2 +4.43% 78 Beta is 3.4260 as of Jun. 24, 2026. GuruFocus rates FRA:RI2 with a GF Score™ of 78/100 and a GF Value™ of €23.45. The stock has 8 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-24), Rigel Pharmaceuticals's Beta is 3.4260.


Rigel Pharmaceuticals  (FRA:RI2) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Rigel Pharmaceuticals Beta Related Terms


Rigel Pharmaceuticals Beta Historical Data

* Premium members only.

The historical data trend for Rigel Pharmaceuticals's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rigel Pharmaceuticals Beta Chart

Rigel Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.92 1.05 1.80 0.52 1.25

Rigel Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.18 1.37 2.07 1.25 2.83

FRA:RI2 vs CBIO, TRAX, GYRE: Beta Comparison

For the Biotechnology subindustry, Rigel Pharmaceuticals's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rigel Pharmaceuticals Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Beta distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's Beta falls into.


FRA:RI2
78GF Score
Rigel Pharmaceuticals Inc FRA:RI2
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rigel Pharmaceuticals Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 3.4260 mean?
Rigel Pharmaceuticals (FRA:RI2) has a Beta of 3.4260 as of Jun. 24, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Rigel Pharmaceuticals and its competitors.
Is Rigel Pharmaceuticals' Beta too high?
Rigel Pharmaceuticals' current Beta is 3.4260. Overall, Rigel Pharmaceuticals has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' Beta compare to CBIO and TRAX?
Rigel Pharmaceuticals' Beta of 3.4260 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Rigel Pharmaceuticals and its competitors. Rigel Pharmaceuticals's current Beta is 3.4260. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Rigel Pharmaceuticals (FRA:RI2) has a current Beta of 3.4260. The stock's GF Value™ is €23.45, compared to a current price of €29.47 — trading 25.7% above its estimated fair value. The current Beta is 3.4260. Rigel Pharmaceuticals' overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Rigel Pharmaceuticals (FRA:RI2), the current Beta is 3.4260 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?

Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued. The current stock price of €29.47 is trading 25.7% above its estimated GF Value™ of €23.45.

Key valuation signals for FRA:RI2:

  • Beta: 3.4260
  • GF Value™: €23.45 vs. price of €29.47 (25.7% above fair value)
  • GF Score™: 78/100 with 8 warning signs

No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Rigel Pharmaceuticals Business Description

Other Exchanges RIGL:USA
Address 611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
78GF Score

Get the complete analysis for FRA:RI2

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€29.47
Price
€23.45
GF Value